NCT04329325View on ClinicalTrials.gov

Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

March 30, 2020

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Acute Lymphoblastic LeukemiaPhiladelphia Chromosome-Positive
Interventions
BIOLOGICAL

Blinatumomab

Please see detailed summary.

DRUG

dasatinib

Please see detailed summary.

DRUG

dexamethasone

Please see detailed summary.

DRUG

methotrexate

Please see detailed summary.

Trial Locations (2)

10029

Mount Sinai Hospital, New York

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT04329325 - Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter